09 March 2021 : Original article
Urinary C-X-C Motif Chemokine 10 Is Related to Acute Graft Lesions Secondary to T Cell- and Antibody-Mediated Damage
Alvaro Arnau1BEF*, Adalberto Benito-Hernández1ABCDEFG, María Angeles Ramos-Barrón1BCDF, María Teresa García-Unzueta2BCDF, José Javier Gómez-Román3BCDF, José María Gómez-Ortega3BCDF, Marcos López-Hoyos4BCDFG, David San Segundo4BCDF, Juan Carlos Ruiz1BCDFG, Emilio Rodrigo1ABCDEFGDOI: 10.12659/AOT.929491
Ann Transplant 2021; 26:e929491
Table 1 Main patient and transplant characteristics and variables related to both clinical and subclinical antibody-mediated rejection (AbMR) and T cell-mediated rejection (TCMR).
| All patients (n=151) | No AbMR (n=99) | AbMR (n=52) | p | No TCMR (n=115) | TCMR (n=36) | p | |
|---|---|---|---|---|---|---|---|
| Recipient age (years) | 49.2±12.6 | 50.6±12.1 | 46.3±13.1 | 0.039 | 50.5±12.0 | 45.3±14.0 | 0.032 |
| Recipient gender (Male) | 61.6% | 63.6% | 57.7% | 0.475 | 67.8% | 41.7% | 0.005 |
| Donor age (years) | 49.9±14.1 | 49.7±13.3 | 50.3±15.7 | 0.798 | 50.2±14.2 | 48.9±13.9 | 0.640 |
| Life donor | 14.6% | 10.1% | 23.1% | 0.032 | 10.4% | 27.8% | 0.010 |
| ECD | 29.1% | 24.2% | 38.5% | 0.068 | 31.3% | 22.2% | 0.295 |
| DCD | 22.5% | 28.3% | 11.5% | 0.019 | 22.6% | 22.2% | 0.961 |
| Mismatches | 4.0±1.3 | 4.0±1.3 | 4.1±1.3 | 0.939 | 4.0±1.4 | 4.1±1.1 | 0.846 |
| CIT (hours) | 14.5±7.9 | 14.1±7.4 | 15.2±8.8 | 0.472 | 15.1±7.7 | 12.4±8.2 | 0.073 |
| SPK | 12.6% | 15.2% | 7.7% | 0.189 | 12.2% | 13.9% | 0.787 |
| Pretransplant DSA | 6.6% | 2.0% | 15.4% | 0.002 | 7.8% | 2.8% | 0.288 |
| Current cPRA (%) | 1.5±10.1 | 0.9±7.6 | 2.4±13.8 | 0.405 | 2.0±11.6 | 0.0±0.0 | 0.073 |
| Peak PRA >25% | 13.9% | 11.1% | 19.2% | 0.171 | 16.6% | 5.6% | 0.097 |
| DSA at biopsy | 27.2% | 10.1% | 59.6% | <0.001 | 21.7% | 44.4% | 0.008 |
| Retransplant | 28.5% | 21.2% | 42.3% | 0.006 | 30.45 | 22.2% | 0.341 |
| Prednisone dose (mg) | 4.5±3.2 | 4.7±3.5 | 4.3±2.5 | 0.469 | 4.4±3.1 | 4.9±3.5 | 0.481 |
| Tacrolimus blood level at biopsy (ng/ml) | 7.9±2.6 | 8.1±2.7 | 7.5±2.4 | 0.176 | 7.9±2.5 | 8.0±2.8 | 0.853 |
| Basiliximab induction | 17.2% | 18.2% | 15.4% | 0.665 | 18.3% | 13.9% | 0.544 |
| Thymoglobulin induction | 50.3% | 49.5% | 51.9% | 0.777 | 53.9% | 38.9% | 0.116 |
| DGF | 21.9% | 17.2% | 30.8% | 0.055 | 24.3% | 13.9% | 0.185 |
| Creatinine at biopsy (mg/dl) | 1.59±0.81 | 1.43±0.69 | 1.90±0.93 | 0.001 | 1.50±0.70 | 1.89±1.04 | 0.010 |
| eGFR at biopsy (ml/min/1.73 m) | 55±24 | 61±23 | 45±20 | <0.001 | 58±24 | 45±21 | 0.002 |
| Proteinuria at biopsy (mg/day) | 940±1656 | 606±1137 | 1579±2226 | 0.004 | 835±1620 | 1275±1748 | 0.165 |
| CXCL10/Cr at biopsy (ng/mmol) | 15.52±15.43 | 12.52±14.24 | 21.24±16.10 | 0.001 | 13.82±15.01 | 20.96±15.67 | 0.015 |
| Logarithm of CXCL10/Cr at biopsy | 1.07±0.31 | 0.98±0.30 | 1.24±0.27 | <0.001 | 1.01±0.31 | 1.23±0.28 | <0.001 |
| CXCL10/Cr 3 tertile | 33.8% | 23.2% | 53.8% | <0.001 | 27.8% | 52.8% | 0.006 |
| ECD – expanded criteria donor; DCD – donation after cardiac death; CIT – cold ischemia time; SPK – simultaneous pancreas and kidney transplant; DSA – donor-specific antibodies; PRA – panel-reactive antibodies; DGF – delayed graft function; eGFR – estimated glomerular filtration rate. | |||||||